Compugen (CGEN) SVP reports RSU and option stakes in Form 3 filing
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
COMPUGEN LTD executive Sharon Kredo Russo, SVP Research & Discovery, filed an initial ownership report showing equity-based compensation rather than any recent share purchases or sales. She holds 19,500 Ordinary Shares in the form of restricted stock units that vest 50% on December 31, 2027, with the remainder vesting in eight equal quarterly installments thereafter, subject to continued service. She also holds a share option covering 26,000 Ordinary Shares at an exercise price of $1.64 per share, expiring November 6, 2035, which vests on the same 50%-then-quarterly schedule, also conditioned on continued service to the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Kredo Russo Sharon
Role
SVP, Research & Discovery
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (right to buy) — 26,000 shares (Direct);
Ordinary Shares — 19,500 shares (Direct)
Footnotes (1)
- Represents restricted stock units ("RSUs") which vest 50% on December 31, 2027 and the remainder vests in 8 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. This option vests 50% on December 31, 2027 and the remainder vests in 8 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
FAQ
What does the Form 3 filing by COMPUGEN LTD executive Sharon Kredo Russo show?
The Form 3 shows Sharon Kredo Russo’s initial equity holdings in COMPUGEN LTD, including restricted stock units and options. It records her starting ownership as an officer, without indicating any recent share purchases or sales in the reported transactions.
What stock options for COMPUGEN (CGEN) does Sharon Kredo Russo hold?
She holds a share option covering 26,000 COMPUGEN Ordinary Shares at an exercise price of $1.64 per share. The option expires on November 6, 2035 and vests 50% on December 31, 2027, with the remainder vesting in eight equal quarterly installments, contingent on continued service.
Are there any buy or sell transactions in Sharon Kredo Russo’s COMPUGEN Form 3?
The Form 3 does not show any buy or sell transactions. It lists two holding entries with transaction direction marked as unknown, serving primarily to disclose her existing restricted stock units and stock option positions rather than report new trading activity.
How do Sharon Kredo Russo’s COMPUGEN RSUs vest over time?
Her COMPUGEN restricted stock units vest 50% on December 31, 2027, with the remaining 50% vesting in eight equal quarterly installments thereafter. All vesting is subject to her continued service to the issuer throughout this multi-year vesting schedule.
What role does Sharon Kredo Russo hold at COMPUGEN (CGEN) in this Form 3?
In the Form 3, Sharon Kredo Russo is identified as an officer of COMPUGEN LTD with the title “SVP, Research & Discovery.” The filing links her reported restricted stock units and stock option holdings to this executive leadership position at the company.